1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Clindamycin Phosphate Vaginal Suppositories

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>CLEOCIN Vaginal Ovule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family</td>
<td>Not determined</td>
</tr>
<tr>
<td>Intended Use</td>
<td>Pharmaceutical product used as antibiotic agent</td>
</tr>
</tbody>
</table>

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin Phosphate</td>
<td>24729-96-2</td>
<td>246-433-0</td>
<td>100 mg ***</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed Glycerides of Saturated Fatty Acids</td>
<td>Not Assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Suppository
Signal Word: WARNING

Statement of Hazard:
May be harmful if swallowed.
May cause allergic reaction.

Additional Hazard Information:
Short Term: May cause eye irritation (based on components). May cause mild skin irritation (based on animal data). An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8).

Known Clinical Effects:
Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur.

EU Indication of danger: Irritant
EU Hazard Symbols:
EU Risk Phrases:

R43 - May cause sensitization by skin contact.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact:  Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact:  Due to the nature of this material first aid is not normally required. If irritation occurs, wash exposed area with soap and water, remove contaminated clothing and obtain medical assistance.

Ingestion:  Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:  Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media:  Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products:  Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire Fighting Procedures:  During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards:  Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:  Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting:  Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections:  Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills:  Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Clindamycin Phosphate

Pfizer OEL TWA-8 Hr: 0.1mg/m³


Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Individuals with known sensitivity should wear protective gloves to avoid skin contact.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities. Individuals with known sensitivity should wear long sleeves to avoid skin contact. Wash hands and arms thoroughly after handling this material.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Suppository

Color: No data available.

Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable at normal conditions

Conditions to Avoid: Keep away from excessive heat and flames.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

<table>
<thead>
<tr>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>1832  mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Intravenous</td>
<td>LD 50</td>
<td>321   mg/kg</td>
</tr>
<tr>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>745   mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Oral</td>
<td>LD 50</td>
<td>2359  mg/kg</td>
</tr>
<tr>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD 50</td>
<td>820   mg/kg</td>
</tr>
</tbody>
</table>
Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate
Eye Irritation  Rabbit  Moderate
Skin Irritation  Rabbit  Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate
6 Month(s)  Rat  Oral  600 mg/kg/day  NOAEL  No effects at maximum dose
6 Month(s)  Dog  Oral  600 mg/kg/day  NOAEL  Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate
Prenatal & Postnatal Development  Rat  Subcutaneous  250 mg/kg  NOAEL  Not teratogenic
Prenatal & Postnatal Development  Rat  Oral  300 mg/kg/day  NOAEL  Not Teratogenic
Prenatal & Postnatal Development  Mouse  Oral  600 mg/kg/day  NOAEL  Not Teratogenic
Prenatal & Postnatal Development  Rabbit  Subcutaneous  5 mg/kg/day  NOAEL  Not Teratogenic, Maternal Toxicity
Reproductive & Fertility  Rat  Oral  300 mg/kg/day  NOAEL  No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate
Bacterial Mutagenicity (Ames)  Salmonella  Negative
In Vitro Micronucleus  Rat  Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: The material should be disposed of by incineration in a chemical incinerator in compliance with national and regional requirements.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

EU Symbol: Xi
EU Indication of danger: Irritant

EU Risk Phrases:
R43 - May cause sensitization by skin contact.

EU Safety Phrases:
S24 - Avoid contact with skin.
S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:
WARNING
May be harmful if swallowed.
May cause allergic reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision B

Clindamycin Phosphate
EU EINECS List 246-433-0

16. OTHER INFORMATION

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet